sexta-feira, 13 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Via News Knowledge File

Qualcomm Incorporated

organization80% conf.·synced Aug 13, 2026

Semiconductor IP licensing and wireless technology company that founded CDMA

55
sourced metrics
343
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
162.88USD
Jul 29, 2026source
Market Share
221.23USD
Jul 29, 2026source
Backlog
65USD
Jun 24, 2026source
Eps
2.65USD
Apr 30, 2026source
Price Target
140USD
Apr 16, 2026source
Previous Price Target
185USD
Apr 16, 2026source
Forward Pe Ratio
12ratio
Apr 1, 2026source
Automotive Design Win Pipeline
45USD
Apr 1, 2026source
Cash
3.7USD
Mar 29, 2026source
Margin
72percent
Mar 29, 2026source
Quarterly Dividend
0.92USD
Mar 25, 2026source
Stock Return
11percent
Mar 25, 2026source
Total Return
229percent
Mar 25, 2026source
Pe Ratio Forward
12ratio
Mar 23, 2026source
Free Cash Flow
12.9USD
Mar 23, 2026source
Dividend Per Share Increase
0.03USD
Mar 20, 2026source
Board Size
11directors
Mar 20, 2026source
Free Cash Flow Return Rate
100percent
Mar 20, 2026source

Stated objectives

Fiscal Q2 2026 revenue forecast

source
target: $10.2-$11 billion by 2026-03-31 00:00:00stated

Fiscal 2029 revenue goals

source
target: Undisclosed by 2029-09-30 00:00:00stated

Fiscal Q2 2026 revenue target

source
target: $10.2-11B stated

Fiscal Q2 2026 EPS target

source
target: $2.45-2.65 stated

Fiscal 2029 revenue goals

source
by 2029-01-01 00:00:00stated

Fiscal Q2 revenue forecast

source
target: $10.2B to $11B stated

Fiscal Q2 EPS forecast

source
target: $2.45 to $2.65 stated

Fiscal 2029 revenue goals

source
by 2029-01-01 00:00:00stated

Q2 revenue forecast

source
target: $10.2 billion to $11.0 billion stated

Qualcomm fiscal Q2 revenue forecast

source
target: $10.2B-$11B stated

Relationship graph · 343 connections

Supplies to
71
Competes with
60
Developed by
41
Customer of
29
Employs
23
Covered by
23
Invested in
13
board member of
11
licensed from
Hop-on, Inc.
licensed to
Hop-on, Inc.
headquartered in
United States

Where sources disagree

We surface conflicts between sources rather than hiding them.

timing conflictunresolved

Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.

source B

Via News coverage

A Aposta de 180 Mil Milhões de Dólares da Alphabet na IA: Estratégia Audaz ou Risco Financeiro?
February 5, 2026
Asus Apresenta Zenbook A16 Ultra-Leve com Potente Processador Snapdragon X2 na CES 2023
February 3, 2026
ChatGPT Transforma Consultas de Saúde: Equilibrando Benefícios e Riscos
January 5, 2026
As Ações Da QUALCOMM Saltam 27% No Início De Sessão
July 22, 2022
As Ações Da QUALCOMM Baixam 8% Até Agora
June 16, 2022
As Ações Da QUALCOMM Sobem 8% Até Agora
April 28, 2022
As Ações Da QUALCOMM Baixam 5% Até Agora
March 7, 2022
As Ações Da QUALCOMM Diminuem 5%
March 1, 2022
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com